

6. (Amended) The sebocyte according to claim 1, characterized in that it expresses a SV-40 large T antigen.

7. (Amended) The sebocyte according to claim 1, characterized in that it exhibits features of a normal, non-transfected and differentiating sebocyte.

8. (Amended) The sebocyte according to claim 1, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

9. (Amended) The sebocyte according to claim 1, characterized in that it is cloned.

---

### **III. Addition of Claims**

Please add the following new claims:

23. (New) The sebocyte according to claim 2, characterized in that it is present in form of a cell line.

24. (New) The sebocyte according to claim 2, characterized in that it is immortalized by transfection of DNA.

25. (New) The sebocyte according to claim 2, characterized in that it expresses a SV-40 large T antigen.

26. (New) The sebocyte according to claim 2, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

27. (New) The sebocyte according to claim 2, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

Cont  
A3

28. (New) The sebocyte according to claim 2, characterized in that it is cloned.

29. (New) The sebocyte according to claim 3, characterized in that it is present in form of a cell line.

30. (New) The sebocyte according to claim 3, characterized in that it is immortalized by transfection of DNA.

31. (New) The sebocyte according to claim 3, characterized in that it expresses a SV-40 large T antigen.

32. (New) The sebocyte according to claim 3, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.


33. (New) The sebocyte according to claim 3, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

34. (New) The sebocyte according to claim 3, characterized in that it is cloned.

35. (New) The sebocyte according to claim 4, characterized in that it is immortalized by transfection of DNA.

36. (New) The sebocyte according to claim 4, characterized in that it expresses a SV-40 large T antigen.

37. (New) The sebocyte according to claim 4, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

 38. (New) The sebocyte according to claim 4, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

39. (New) The sebocyte according to claim 4, characterized in that it is cloned.

40. (New) The sebocyte according to claim 5, characterized in that it expresses a SV-40 large T antigen.

41. (New) The sebocyte according to claim 5, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

42. (New) The sebocyte according to claim 5, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

43. (New) The sebocyte according to claim 5, characterized in that it is cloned.

44. (New) The sebocyte according to claim 6, characterized in that it exhibits a feature of a normal, non-transfected and differentiating sebocyte.

45. (New) The sebocyte according to claim 6, characterized in that its proliferation is modifiable by an androgen and/or a retinoid.

46. (New) The sebocyte according to claim 6, characterized in that it is cloned.

47. (New) The sebocyte according to claim 7, characterized in that its proliferation is modifiable by an androgen and/or retinoid.

48. (New) The sebocyte according to claim 7, characterized in that it is cloned.

49. (New) The sebocyte according to claim 8, characterized in that it is cloned.

50. (New) A method of diagnosis, treatment, or cosmetic enhancement, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for a diagnostic, therapeutic or cosmetic purpose.

51. (New) A method for examination of physiology or pathophysiology of a human or an animal sebaceous gland, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the examination of the physiology or the pathophysiology of the human or animal sebaceous gland.

52. (New) A method for examination of origin of acne and/or seborrhea and/or other disease, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the examination of the origin of acne and/or seborrhea and/or other disease.

53. (New) The method according to claim 52, wherein the other disease to be examined is skin disease in which a sebaceous gland function is involved or may be involved.

Cont  
A3

54. (New) A method of for testing of an anti-acne and/or an anti-seborrhea compound or agent, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the testing of the anti-acne and/or the anti-seborrhea compound or agent.

55. (New) A method for testing of a compound or an agent against a disease, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the testing of the compound or the agent against the disease.

56. (New) The method according to claim 55, wherein the disease is a skin disease in which a sebaceous gland function is involved or may be involved.

57. (New) A method for development of a simple or a complex cell culture system, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the development of the simple or the complex cell culture system.

58. (New) A method for formation of or for use in a three-dimensional cell aggregation or construction of an organ-type structure, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the formation of or for the use in the three-dimensional cell aggregation or for the construction of the organ-type structure.

Ortl  
#2

59. (New) A method for preparation of a cell product, comprising: providing the sebocyte set forth in any of claims 1-9, 23-49, or the human sebocyte cell line according to claim 10, and using the sebocyte or the human sebocyte cell line for the preparation of the cell product.

60. (New) The method according to claim 59, wherein the cell product is a lipid, a plasmid, a vector, or a protein which is expressed by the cell and/or a DNA or a RNA sequence of the protein.

61. (New) A method of using the product obtained according to claim 59 for modification of another cell or modification of an organism, comprising: obtaining the product and using the product to modify the other cell and/or the organism.

62. (New) A method of using the product obtained according to claim 60 for modification of another cell or modification of an organism, comprising: obtaining the product and using the product to modify the other cell and/or the organism.

---

### REMARKS

In the Office Action dated September 12, 2002, claims 1-22 were rejected and claims 5-9 and 11-22 were objected to. Upon entry of this Amendment, claims 1-10 and 23-62 are pending and under consideration in the present application.

Applicant respectfully submits that no new matter has been added by way of this amendment.

#### ***I. Claim for Priority***

The Office acknowledges Applicant's claim for priority but notes that Applicant has not filed a certified copy of the application as required by 35 U.S.C. § 119(b). Applicant has